Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Filters

2014 - 20152

Settings

search.filters.applied.f.language: search.filters.language.turSubject: search.filters.subject.Prostate cancer

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Lympadenectomy in Prostate Cancer
    (2014) Kosan, Murat
    Aim: Radical prostatectomy is the standard treatment in localized prostate cancer. The limited or extended lymph node dissection in pelvic region is additionally applied to this procedure. We aimed to review the publications about the recently popularized extended pelvic lymph node dissection (PLND). New Findings: The extended PLND is not suggested in patients with low risk prostate cancer. On the other hand, extended PLND is suggested to make a good staging and treat the micrometastasis in patients with intermediate and high risk prostate cancer. The complication rates of PLND are acceptable in comparison with the benefits. The benefits of other expansive methods for clinical staging are still lower than PLND. Conclusion: However, prospective and randomized clinical trials are needed to investigate the efficiency of PLND in localized prostate cancer, PLND has important role with good oncological results in patients with intermediate and high risk prostate cancer.
  • Thumbnail Image
    Item
    Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer
    (2015) Kervancioglu, Enis; Kosan, Murat
    Prostate cancer, is the most commonly diagnosed cancer in the United States and in many parts of the world and ranks 2nd in death from cancer among men. Lifetime risk of developing prostate cancer is 16%. Currently the only accepted screening tool Prostate Specific Antigen (PSA) and Digital Rectal Examination (DRE). PSA is a specific biomarker but non-specific for prostate cancer. In diseases such as Benign Prostatic Hyperplasia (BPH) and prostatitis high serum PSA levels can be detected. Therefore, identifying prostate cancer only with serum PSA measurement has lower specificity and may lead to false positive results and unnecessary biopsies. Some encountered problems such as unnecessary diagnoses of clinically insignificant cancer and the non-diagnosis of early stage cancers can take. In recent years there are too many studies to investigate new biomarkers for replacing or helping PSA. The aim of this article was the evaluation of the current situation for PSA and non-PSA tissue and serum biomarkers which are published.